BioNTech Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 1,941
Employees
  • Stock Symbol
  • BNTX
Stock Symbol
  • Investments
  • 12
  • Share Price
  • $212.42
  • (As of Friday Closing)

BioNTech General Information

Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact Information

Website
www.biontech.de
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • An der Goldgrube 12
  • 55131 Mainz
  • Germany
+49 06131 00000

BioNTech Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioNTech Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$212.42 $214.20 $49.91 - $252.78 $51.7B 242M 3.01M $5.77

BioNTech Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 24,725,619 18,809,932 7,267,406
Revenue 2,916,132 549,808 121,559 150,547
EBITDA 1,856,856 (121,536) (162,999) (30,626)
Net Income 1,394,168 17,324 (200,443) (56,666)
Total Assets 4,929,135 2,851,826 893,502 746,953
Total Debt 298,465 11,244 5,945 71,476
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioNTech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioNTech‘s full profile, request access.

Request a free trial

BioNTech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualiz
Biotechnology
Mainz, Germany
1,941 As of 2020
00.000
00000000 00.000

00000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
Norcross, GA
0 As of 0000
000000000000

0000 000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000 000000000
Cambridge, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioNTech Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Galectin Therapeutics Corporation Norcross, GA 0 000000000000
0000 0000 00000000 Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
000000 00000000 Venture Capital-Backed Williamsville, NY 00 00.000 000000000 - 00.000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000000 00000
You’re viewing 5 of 37 competitors. Get the full list »

BioNTech Executive Team (17)

Name Title Board Seat Contact Info
Ugur Sahin MD Co-Founder and Chief Executive Officer
Sierk Poetting Ph.D Chief Financial Officer and Chief Operating Officer
Ryan Richardson Chief Strategy Officer, Strategy
Sean Marett Chief Business Officer & Chief Commercial Officer
Christopher Huber MD Co-Founder & Deputy Chair Supervisory Board
You’re viewing 5 of 17 executive team members. Get the full list »

BioNTech Board Members (4)

Name Representing Role Since
Christopher Huber MD BioNTech Co-Founder & Deputy Chair Supervisory Board 000 0000
Helmut Jeggle Self Chairman & Board Member 000 0000
Michael Motschmann Ph.D MIG AG Board Member 000 0000
Michael Motschmann BioNTech Board Member 000 0000
To view BioNTech’s complete board members history, request access »

BioNTech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioNTech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioNTech‘s full profile, request access.

Request a free trial

BioNTech Investments & Acquisitions (12)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 (000 09-May-2021 00000 0000000 Pharmaceuticals 0000 00000 00
00 0000000000 000 25-Nov-2020 00000 0000000 Drug Discovery 0000 00000 00
00000000 00 (000 0 01-Oct-2020 000000000 00000 00 Buildings and Property 00000 00000000 00.0
00000000 (0000000 17-Sep-2020 000000000 00000 00 Buildings and Property
Neon Therapeutics 06-May-2020 Merger/Acquisition 0000 Drug Discovery 0000 00000 00
You’re viewing 5 of 12 investments and acquisitions. Get the full list »

BioNTech Subsidiaries (1)

Company Name Industry Location Founded
000000 Biotechnology Idar-Oberstein, Germany 0000
To view BioNTech’s complete subsidiaries history, request access »